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Abstract: Cholinesterases are important biological targets responsible for regulation of 
cholinergic transmission, and their inhibitors are used for the treatment of Alzheimer’s 
disease. To design new cholinesterase inhibitors, of different structure-based design 
strategies was followed, including the modification of compounds from a previously 
developed library and a fragment-based design approach. This led to the selection of 
heterodimeric structures as potential inhibitors. Synthesis and biological evaluation of 
selected candidates confirmed that the designed compounds were acetylcholinesterase 
inhibitors with IC50 values in the mid-nanomolar to low micromolar range, and some of 
them were also butyrylcholinesterase inhibitors. 
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1. Introduction 
Since the cholinergic hypothesis was approved, cholinesterases have become important therapeutic 
targets in Alzheimer’s disease (AD) treatment [1]. The mechanism of action of cholinesterase 
inhibitors comprises the increase of cholinergic transmission in the central nervous system, defects of 
which lead to memory and thinking disturbances. Nevertheless, this kind of treatment is not fully 
effective and the search for new drugs involves different therapeutic possibilities. Currently, only 
drugs from the cholinesterases inhibitors group, such as rivastigmine, donepezil and galantamine, and 
from the N-methyl-D-aspartate (NMDA) antagonist group, such as memantine, have been approved 
(Figure 1) [2,3]. During the last few years, it has been shown that cholinesterases can influence a series 
of other processes, such as β-amyloid aggregation, due to the presence of a peripheral anionic site 
(PAS) in their structure [4,5].  
These discoveries led to a resurgence of interest in cholinesterases as an important target in the 
therapy of Alzheimer’s disease, and numerous research groups have undertaken investigations 
concerning design and synthesis of new inhibitors [6,7]. 
Figure 1. Cholinesterases inhibitors used in Alzheimer’s disease (AD) treatment.  
Tacrine was withdrawn, due to its hepatotoxicity, but it is still used in experiments as a  
reference inhibitor. 
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Cholinesterases differ in substrate specificity and susceptibility to various kinds of inhibitors [8,9]. 
Due to these differences, they were divided into two types: acetylcholinesterase (AChE), which 
hydrolyzes acetylcholine, and butyrylcholinesterase (BuChE), which is able to hydrolyze larger 
molecules, such as butyrylcholine. Both cholinesterases belong to a large protein family containing the 
α/β hydrolase fold [10,11]. Acetylcholinesterase is the main enzyme metabolizing acetylcholine. It is 
also responsible for cerebral blood flow modulation, β-amyloid aggregation, activation and expression 
of APP95 protein, τ protein phosphorylation and has an influence on inflammatory processes. It 
interacts with β-amyloid, leading to creation of stable complexes and formation of senile  
plaques [12,13]. The other enzyme—butyrylcholinesterase—is also important, because of its ability to 
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hydrolyze acetylcholine and other choline esters. It was observed that the BuChE level increases in AD 
patients. Its role is not fully understood, but some studies suggested that it could promote amyloid 
plaque formation, and therefore, the search for inhibitors of both enzymes has been undertaken [6,14]. 
The structure of AChE was first described in 1991 by J. Sussman, who successfully crystallized the 
enzyme from the electric organ of the electric ray, Torpedo californica (TcAChE) [15]. TcAChE is 
composed of 537 amino acids and contains 12 β-sheets surrounded by 14 α-helices. BuChE is very 
closely related to AChE; therefore, all structural analyses were performed with a homology model of 
BuChE based on electric ray acetylcholinesterase, until its structure was solved [16]. 
The hydrolysis reaction takes place in the catalytic site of AChE, located at the bottom of a deep, 
and narrow gorge (20 Å deep, 5 Å wide), which is composed of conserved aromatic amino acids 
(Figure 2). This most important site, called also the esteratic site, contains the three essential amino 
acids, Ser200, His440 and Glu327 (TcAChE), which create the catalytic triad. They are involved in the 
transfer of the acetyl group from acetylcholine to Ser200. The catalytic triad of human BuChE is built 
of Ser198, His438 and Glu325. An essential role in the hydrolysis process is also played by aromatic 
amino acids, such as Trp84 and Phe330 [17]. The AChE anionic site, composed of Trp84, Tyr130, 
Phe330 and Phe331, is responsible for binding the substrate quaternary ammonium group with  
cation-π interactions. Due to the interactions with the anionic site, the proper orientation of 
acetylcholine in the gorge is provided. It also enables inhibitor binding to the enzyme. In BuChE, the 
tryptophan key residue (Trp82) is conserved, but one phenylalanine (Phe330) is replaced by Ala328. 
The lack of this phenylalanine influences the affinity of some inhibitors. For example, huperzine is 
characterized by high affinity to AChE, because its protonated primary amine creates strong 
interactions with Phe330 from TcAChE, whereas affinity to hBuChE is lower, due to the presence of 
Ala328 in this place [18,19]. One of the serine hydrolase features is stabilization of the transition state 
by amino acids of the oxyanion hole through hydrogen-bond creation. During the enzymatic reaction, 
the transition complex is created and stabilized by Gly118, Gly119 and Ala201 from AChE. In 
hBuChE, the oxyanion hole is similar and consists of highly conserved N–H dipoles, derived from 
amino acids of the main chain: Gly116, Gly117 and Ala119. The acyl pocket is responsible for 
substrate specificity (Figure 3). Comparison of hBuChE and TcAChE shows differences in size, 
especially of the acyl binding pocket. The active gorge is larger in hBuChE than in TcAChE (500 Å3 
versus 300 Å3). The active site in TcAChE is lined by 14 aromatic residues [20], in BuChE, six of 
them are replaced by smaller aliphatic residues, even polar ones. The shape of the acyl pocket is 
determined by two residues: these are the aromatic amino acids Phe288 and Phe290 in TcAChE, but 
the aliphatic residues Leu286 and Val288 in hBuChE. Phe288 and Phe290 prevent access of larger 
molecules to the catalytic center. In the case of BuChE, the replacement of two phenylalanine residues 
by the smaller amino acids, valine and leucine, makes the hollow in the acyl pocket larger and enables 
larger molecules to get in, which results in lower enzyme specificity. The AChE peripheral anionic site 
(PAS) consists of five amino acids—Tyr70, Asp72, Tyr121, Trp279 and Tyr334. The PAS is located 
at the entry to the active gorge and is responsible for extra activities, including the interaction with  
β-amyloid [15,21]. BuChE does not own counterparts of Tyr70, Tyr121 and Trp279 in the peripheral 
site. The PAS is a very important structural element, responsible also for binding of many inhibitors. 
These differences in the structure of the active sites can explain the majority of the activity 
differences of the two enzymes. 
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Figure 2. Active site of acetylcholinesterase (Torpedo californica acetylcholinesterase 
(TcAChE); Protein Database Bank (PDB): 1EVE). 
 
Figure 3. Active site of butyrylcholinesterase (human butyrylcholinesterase (hBuChE), 
PDB: 1P0I). 
 
Alignment of the crystal structures of native AChE and its complexes with inhibitors (tacrine THA, 
PDB: 1ACJ; decamethonium, DECA, PDB: 1ACL; m-(N,N,N-trimethylammonio)-trifluoroacetophenone, 
TMTFA, PDB: 1AMN; huperzine, HUP, PDB: 1VOT; edrophonium, EDR, PDB: 2ACK; donepezil, 
E2020, PDB: 1EVE) highlighted conformational changes of Phe330 and Trp279 upon ligand binding 
(Figure 4). In addition, the crucial role of conserved water molecules was revealed [22]. Phe330 can 
adopt a wide range of conformations in complexes with inhibitors. Based on its χ1 angle values, AChE 
crystal structures can be divided into three groups: group A—similar to native AChE: 2ACE  
(χ1 = −162°), 1AMN (χ1 = −174°), 1VOT (χ1 = −171°), 2ACK (χ1 = −177°); group B—similar to 
AChE in complex with tacrine: 1ACJ (χ1 = 157°); and group C—similar to AChE in complex with 
donepezil: 1EVE (χ1 = −130°), 1ACL (χ1 = −117°). Group A includes inhibitors, which bind near the 
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bottom of the active gorge. In the case of tacrine (group B), the phenyl ring of Phe330 is placed over 
the ligand molecule and creates together with the indole moiety of Trp84 a characteristic sandwich 
with the inhibitor between them. Group C includes inhibitors extended along the active gorge, which 
causes location of Phe330 near the wall of the gorge. In the case of group B, there is also a different 
conformation of Trp279 in comparison to the native enzyme or AChE from other complexes (χ2 = 30° 
and 90°, respectively). This may suggest the presence of a special linkage between the anionic subsite 
and the peripheral anionic site. It is interesting to note that the side chains of other amino acids are 
relatively rigid in comparison to Phe330. The presence of this residue also leads to the increased 
catalytic activity of acetylcholinesterase relative to butyrylcholinesterase (which does not contain Phe330). 
Figure 4. Superimposed amino acid residues from the AChE active site, derived from 
different crystal structures (1ACJ: yellow; 1EVE: blue; 2ACE: red; 2CKM: green). 
 
All crystal structures of complexes of AChE with inhibitors contain many water molecules. Among 
them, there are buried water molecules, which are closed inside restricted areas, and conserved waters, 
which are almost always present in the same position, regardless of the complex. Most important for 
the drug design process are conserved waters in the active site, because they are often involved in 
ligand binding. The analysis of five crystal structures of AChE complexes showed many water 
molecules, present in the active gorge and engaged in creation of hydrogen bonds [23]. There are 20 
water molecules in the active site of AChE from 2ACE, 15 from 1VOT, 18 from 2ACK, 16 from 
1EVE and 22 from 1VXR. 
In the active center of BuChE, derived from four different complexes, 31 conserved water 
molecules were observed. They might be important, due to their ability to create interactions with 
ligands and enzymes by so-called water bridges. 
The search for new active substances from the group of cholinesterases inhibitors has revealed 
various classes of chemical compounds. The literature presents several studies concerning the 
derivatives of drugs, such as physostigmine, rivastigmine, tacrine, donepezil, galantamine or  
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huperzine [6,24]. Recent literature data presents very active, selective inhibitors towards both enzymes 
or non-selective inhibitors [25–27]. 
On the other hand, the research also involves multitarget directed ligands, i.e., compounds that join 
anticholinesterase activity with beta-amyloid anti-aggregation properties, inhibition of monoamine 
oxidase, β-secretase, histamine H3 receptor antagonism, metal-complexing properties, voltage-dependent 
calcium channel antagonistic activity, serotonin reuptake inhibition or with antioxidant and 
neuroprotective properties [28,29]. Generally, such multifunctional ligands showed lower biological 
potency towards all targets in comparison with selective ligands. Among them, dual binding site 
cholinesterases inhibitors represent a valuable therapeutic strategy for further development of potential 
anti-AD agents [30,31].  
Our research group has been involved in the development of cholinesterases inhibitors as potential 
anti-AD drugs. The results of previous studies [32,33] were the starting point of this research. We have 
obtained different series of compounds, among which hybrid structures with an N-benzyl piperidine 
moiety were the most interesting, as they showed inhibition of both cholinesterases with activities in 
the micromolar range. Two of them are presented in Figure 5. Previous docking studies showed a high 
analogy in the context of interactions with cholinesterases. These compounds were dual binding site 
inhibitors. They were arranged along the gorge of acetylcholinesterase, creating characteristic π–π 
stacking interactions with Trp84 in the catalytic site by the benzyl substituent and with Trp279 at the 
peripheral anionic site by heteroaromatic moiety. They also formed a cation-π interaction with  
the Phe330 residue. In addition, there were other interactions stabilizing the inhibitor-AChE complex, 
such as hydrogen bonds involving water molecules. In the case of butyrylcholinesterase, the 
benzylpiperidine moiety interacted with Trp82 and the phthalimide fragment in the acyl pocket 
(Leu286, Val288) [32].  
Figure 5. The starting point of our research—compounds 1 and 2. They are both  
acetyl- and butyryl-cholinesterase inhibitors with micromolar IC50 values [32]. 
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1. AChE: IC50 = 18.2 M; BuChE: IC50 = 22.8 M
2. AChE: IC50 = 53.7 M; BuChE: IC50 = 24.5 M  
These results prompted us to design novel dual binding site cholinesterases inhibitors with 
improvement of inhibitory activities. Herein, we describe in detail the results of an extensive molecular 
modeling study for the design of cholinesterase inhibitors. For this purpose, the molecular 
modifications approach of our active compounds and fragment-based design have been applied.  
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2. Results and Discussion 
2.1. Analysis of Enzyme Structures 
2.1.1. Acetylcholinesterase 
The Protein Data Bank (PDB) contains 122 crystal structures of acetylcholinesterase complexed 
with different ligands [34]. From these complexes, 11 with the most popular ligands were selected. 
These are the complexes with the following ligands: tacrine, decamethonium, edrophonium, 
galantamine, donepezil, rivastigmine, huperzine A, acetylcholine (modeled into native structure), 
ganstigmine, bis-7-tacrine and pralidoxime (abbreviations are described in the caption to Table 1). 
They are characterized by acceptable resolution from 2.15 Å for bis-7-tacrine to 2.80 Å for 
edrophonium. Mutual complex comparison using the program PyMOL [35] showed that  
root-mean-square deviation (rmsd) values for all protein atoms are in the range from 0.702 Å to about 
5 Å. Due to the key role of the amino acids contained in the active center, a detailed structural analysis 
of this part of the enzyme was conducted. The obtained rmsd values are summarized in Table 1. 
Table 1. Comparison of the TcAChE active site from different crystal complexes from the 
PDB: root-mean-square deviation (rmsd) values in Å for all atoms: the amino acids 
included in the comparison are presented in Figure 2. 
PDB 1ACJ 1ACL 1AX9 1DX6 1EVE 1GQR 1VOT 2ACE 2BAG 2CKM 2VQ6 
1ACJ 0 1.062 0.784 0.915 0.907 1.030 0.803 0.830 0.907 1.059 0.751 
1ACL  0 0.728 0.732 0.691 0.850 0.706 0.757 0.663 1.144 0.852 
1AX9   0 0.722 0.714 0.760 0.274 0.617 0.692 0.878 0.536 
1DX6    0 0.366 0.711 0.720 0.511 0.318 0.934 0.614 
1EVE     0 0.634 0.710 0.488 0.236 0.975 0.641 
1GQR      0 0.781 0.625 0.579 1.040 0.743 
1VOT       0 0.594 0.692 0.915 0.581 
2ACE        0 0.443 0810 0.573 
2BAG         0 0.958 0.627 
2CKM          0 0.844 
2VQ6           0 
Complexes with inhibitors: 1ACJ—tacrine, 1ACL—decamethonium, 1AX9—edrophonium, 1DX6—galantamine, 
1EVE—donepezil, 1GQR—rivastigmine, 1VOT—huperzine A, 2ACE—native, 2BAG—ganstigmine,  
2CKM—bis-7-tacrine, 2VQ6—pralidoxime; green color means the pair with the smallest differences; red color means the 
pair with the largest differences. 
The analysis confirmed the relatively high degree of structural conservation of amino acids in 
acetylcholinesterase and conformational changes of Phe330 and Trp279, which was mentioned in the 
literature [22]. 
2.1.2. Butyrylcholinesterase 
The PDB contains 31 structures of butyrylcholinesterase complexes with ligands [34]. Among 
them, four structures (1P0I, 1P0M, 1P0P, 1P0Q) were selected for further analysis. These were 
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complexes with products of hydrolysis of the substrate, i.e., butyrate and choline, and with the 
substrate analogue, i.e., butyrylthiocholine after soman inhibition. They were characterized by good 
resolution within 2.0–2.43 Å. The selected structures were compared with PyMOL [35]. Rmsd values 
for all protein atoms were in the range 1.025–1.596 Å, which indicates, as in the case of AChE, a high 
similarity of the 3D structure of the enzymes from different complexes. It should also be noted that 
butyrylcholinesterase is devoid of the two amino acid residues corresponding to Phe330 and Trp279 in 
AChE, which were characterized by high conformational freedom. Analysis of BuChE complexes, 
taking into account the presence of water molecules, showed that there were 31 water molecules 
present in the active center of these four complexes. They were used during the docking of ligands to 
the active center of BuChE. 
2.2. Validation of Docking with Gold Software  
It was decided to use seven crystal complexes with the non-covalently bound inhibitors (1EVE, 
1ACJ, 2CKM, 1DX6, 1ACL, 1AX9 and 1VOT) for redockings to acetylcholinesterase to optimize the 
parameters associated with the process of docking. The size of binding site, presence of water 
molecules and scoring function were taken into account. Table 2 summarizes the best settings for all 
redocking processes with Gold Software [36]. 
Table 2. Optimal settings of Gold for redockings of seven reference inhibitors. 
Complex 
Binding  
site-radius (Å) 
Water molecules Scoring function 
Value of scoring 
function 
rmsd (Å) 
1EVE 10 
1159, 1249, 1254 
(toggle *) 
ChemScore 49.48 0.8 
1ACJ 12 
616, 634, 643 
(toggle) 
GoldScore 67.95 0.4 
2CKM 10 None GoldScore 80.72 1.3 
1DX6 12 None GoldScore 59.34 0.6 
1ACL 10 None GoldScore 40.45 1.6 
1AX9 12 None ChemScore 26.36 1.4 
1VOT 12 619, 680 (toggle) ChemScore 41.60 0.9 
* The program decides at the step of docking if the water molecule is engaged in ligand binding. 
In the next step, cross-dockings were performed. Each inhibitor was docked to the enzyme from 
each complex, using settings from Table 2 with respect to the protein. The quality of fit was evaluated 
on the basis of ligand rmsd values (Table 3) with the following ranges: 
 rmsd ≤ 1.0 Å, good pose; 
 Å < rmsd ≤ 2.0 Å, close pose; 
 Å < rmsd ≤ 3.0 Å, pose with errors; 
 rmsd > 3.0 Å, bad pose. 
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Table 3. Results of cross-dockings to seven analyzed crystal structures of AChE. 
Assessment with rmsd values (blue: good pose; green: close pose; yellow: pose with errors; 
pink: bad pose). 
 1EVE 1ACJ 2CKM 1DX6 1ACL 1AX9 1VOT 
donepezil 0.8 9.3 10.3 2.6 3.4 2.9 9.6 
tacrine 7.6 0.4 2.9 6.0 5.3 9.6 6.1 
bis-7-tacrine 4.3 5.7 1.3 5.1 5.1 4.8 5.0 
galantamine 1.1 3.7 0.8 0.6 6.2 8.7 4.9 
decamethonium 1.4 3.2 2.3 2.5 1.6 3.2 2.4 
edrophonium 4.5 2.8 2.2 2.3 2.4 1.4 2.0 
huperzine A 5.0 5.0 3.5 3.6 5.0 3.7 0.9 
The performed cross-dockings showed that the best structure of the enzyme that could adopt new 
AChE ligands was one from the complex 1EVE, to which it was possible to dock three inhibitors with 
rmsd in the range between 0.8 and 1.4 Å. The structure of acetylcholinesterase from the complex with  
bis-tacrine was also suitable. Other enzymes only allowed for a good docking of the ligand with which 
they were crystallized. In further studies, it was decided to use the structure of acetylcholinesterase 
from the 1EVE complex, due to the structural similarities of donepezil and the analyzed compounds, 
especially from our own library. The studies related to the search for new inhibitors were also designed 
to obtain new compounds capable of interaction with both the active site and the PAS. The choice of 
the 1EVE structure also seemed to be right due to this reason. 
In the case of butyrylcholinesterase, the docking validation process was more difficult, because 
most of the available crystal structures were complexes with organophosphorus compounds, which 
irreversibly block the enzyme, due to the formation of a covalent bond. It was decided to modify the 
validation of the docking, using some information from the literature [8]. Structure 1P0I and tacrine, 
an inhibitor of both cholinesterases, were chosen as the basis for validation. In the PDB database, there 
is a crystal structure of AChE available with this inhibitor (1ACJ), so in the first stage of the study, the 
structure of both enzymes was compared. The superimposition of the two structures in the PyMOL 
program gave an rmsd value equal to 3.725 Å for all protein atoms. High similarity (73% aa) and 
identity (53% aa) suggested large similarities in the structure of the enzymes and the possibility of 
interaction between tacrine and BuChE in a similar way. Tacrine was docked into the enzyme, 
according to the method described in the Experimental section. There were two main clusters of 
solutions. One of them was almost identical to the arrangement of tacrine in the complex 1ACJ, and 
the second one contained the tetrahydroacridine moiety still in the same plane, but turned. The benzene 
and cyclohexene rings replaced each other. The top-ranked pose obtained a value of 52.63 for the 
ChemScore function. In both cases, the characteristic π–π stacking for tacrine and the residue of Trp82 
was observed (Figure 6). Based on the obtained results, it was decided to use BuChE from 1P0I 
complex and the described settings for further studies. 
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Figure 6. Tacrine clusters obtained in docking to BuChE. Results were compared with the 
arrangement of tacrine (orange) in the complex with acetylcholinesterase. 
 
2.3. Modifications of Heterodimeric Structures from Our Library 
Isoindoline-1,3-dione derivatives (Figure 5) were the basis for the initial design of novel inhibitor 
structures. To improve the activity, some modifications of heterodimeric molecules were introduced. 
They concerned all fragments of the molecule: the heteroaromatic moiety, the linker and the 
substituent in the N-benzylpiperidinylamine group. The structural changes of these compounds tested 
in silico are illustrated in Figure 7. 
Figure 7. Modifications of heterodimeric compounds 1 and 2. 
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The structures of complexes obtained in the process of docking were accurately analyzed to find 
beneficial changes improving binding. The influence of all modifications on the binding was assessed 
by the ChemScore function and inspected visually. 
The first step of the analysis included changes of the heteroaromatic moiety. Five heterocyclic 
systems were taken into account: phthalimide, indole, tetrahydroisoquinoline, tetrahydroquinoline and 
isoindoline. Initial investigations were carried out for the derivatives with a three-carbon linker, which 
was characteristic for compound 1. It was shown that phthalimide had provided the most profitable 
interactions with acetylcholinesterase and had the highest score. It is worth noting that this moiety is 
similar to the indanone present in the donepezil structure and may be considered as a bioisostere. The 
benzylpiperidine moiety interacted with Trp84 by π–π stacking, the protonated piperidine created 
cation-π interactions with Phe330 and a hydrogen bond with a water molecule. The amine group 
interacted with Tyr334 (cation-π). The phthalimide created π–π stacking with Trp279 and CH-π 
interactions with Tyr70. This moiety was favored, because it formed two extra H-bonds by carbonyl 
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groups: one with a water molecule and the other with the hydroxy group of Tyr121. The other 
heterocyclic moieties were assessed lower. The same analysis was performed for the derivatives of 
compound 2 with a six-carbon tether. In this case, all heterocyclic systems had a similar score. It was 
possible, because the longer chain made the phthalimide slightly shift and its carbonyl groups formed 
much weaker hydrogen bonds. 
The second step of the analysis included further changes of tether length (four and eight carbon 
atoms). Compounds with four methylene groups and different heterocyclic moieties were similarly 
assessed as the derivatives with a three-carbon chain. In case of compounds with the longest linker  
(8-CH2–), the differences were enhanced to the advantage of three moieties: isoindoline, 
tetrahydroquinoline and indole. It might be caused by π–π stacking of these moieties with Trp279, 
which was more profitable than the interactions formed by phthalimide. 
The third stage of the analysis included the influence of substituents in the N-benzylpiperidine 
moiety on the activity. The presence of halogen atoms, hydroxy, methoxy, trifluoromethyl and 
carbamate groups in different positions was evaluated. Docking results showed that the enzyme, which 
has a relatively limited space within the gorge, might accept only the compounds with small 
substituents, such as halogens or hydroxyl group. Compounds with hydroxy group, fluorine and 
chlorine showed similar binding modes. All interactions described earlier were kept; the hydroxy 
group and fluorine gave an extra H-bond. Larger substituents forced molecules to make a small shift 
such that the N-benzylpiperidine could not create similarly beneficial interactions with Trp84 and 
Phe330. It turned out that the optimal position of the hydroxy group is a para substitution, because it 
was particularly preferred to the creation of a hydrogen bond with Glu199. For the fluorine atom the 
preferred position was ortho, due to interaction with Ser200, and for the chlorine atom meta. 
According to this analysis, the following compounds were selected as potential AChE inhibitors:  
p-hydroxy, m-chloro and o-fluoro derivatives of compounds 1 and 2 and similar substituted analogues 
with isoindoline, tetrahydroquinoline or indole and eight-carbon linker. 
Analysis of the binding modes of the selected compounds with butyrylcholinesterase suggested that 
only the introduction of the same substituent (OH, Cl, F) in the N-benzylpiperidinyl moiety could 
slightly improve activity, whereas other structural changes could not change the activity to a large extent. 
One of the designed structures, compound 3 (Figure 8), was synthesized and tested in Ellman’s 
assay [37]. It corresponds to the m-chloro derivative of compound 2. The small structural modification 
of a chlorine atom in the meta position increased the activity against both targets: in the case of AChE, 
from 53.7 to 44.0 μM, and in the case of BuChE, from 24.5 to 7.66 μM. 
Figure 8. The obtained derivative 3, based on our library of compounds. 
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3. AChE: IC50 = 44.0 M; BuChE: IC50 = 7.66 M
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Figure 8. Cont. 
 
2.4. Fragment-Based Design of Cholinesterase Inhibitors  
According to the fragment-based methodology [38], a group of structurally simple fragments was 
chosen (Figure 9), and areas where they created optimal interactions with the enzyme were identified 
by means of the docking procedure. 
Figure 9. Structural fragments used for the fragment-based design of cholinesterase 
inhibitors. ChemScore values for binding with acetylcholinesterase are given for  
each fragment. 
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In the case of AChE for the aromatic compounds, π–π stacking and hydrophobic interactions with 
Phe330, Phe331 and Tyr334 residues and, in some instances, with Trp84 or Trp279, were found. 
Piperidine, piperazine and morpholine formed cation-π interactions with these residues. Additionally, 
these heterocyclic rings could create hydrogen bonds with Asp72 and His440. Acridine, aniline and 
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triethylamine formed a hydrogen bond with Tyr121, but benzenesulfonamide with Tyr121, Tyr334  
and Asp72. 
With reference to BuChE, the aromatic compounds formed π–π stacking and hydrophobic 
interactions mainly with Trp82, Trp430 or Trp231. Hydrogen bonds with Asp70 and Tyr332 for 
aniline and benzenesulfonamide were also observed. Piperidine, piperazine, morpholine and 
triethylamine formed cation-π interactions with Trp82 and Trp430; cyclic amines also created 
hydrogen bonds with Tyr332 and, in some cases, additionally with Asp70. 
Based on these fragments, some hybrid structures were designed (Figure 10). Each heterodimer 
contained two fragments, connected by a different kind of tether. The most popular fragment was 
phthalimide. It was present in most compounds (4–9), because it created, except for π–π stacking, two 
H-bonds in the PAS of AChE, which made it a preferable moiety. The peripheral anionic site of 
BuChE is smaller, which explains why compounds bound poorly with that enzyme. The second 
fragment interacted with the catalytic active site (CAS). Ligands 4 and 5 included a benzylamine. This 
change increased the basicity in comparison with other amines and improved cation-π interactions with 
Phe330. The best tether length for those compounds was five to six. Compound 6 was a simple 
modification of compound 5. It contained a fluorine atom in the benzyl moiety in the ortho position. 
Due to this substituent, an extra interaction with the hydroxy group of Ser200 was formed. Compounds 
7–9 included triethylamine as the second fragment. One of the ethyl substituents in triethylamine was 
incorporated in the linker. The tether length was in the range of six to eight, with the optimum equaling 
eight. Protonated amine gave cation-π interactions with Trp84 and Phe330. The assessment of novel 
ligands was based on the docking procedure. The obtained ligand-enzyme complexes were analyzed 
visually and evaluated using the ChemScore function (Table 4). At the step of validation, it was shown 
that compounds with IC50 (AChE) < 1 μM obtained a ChemScore higher than 40; therefore, ligands for 
which the scoring function reached that value (compounds 4–8; exception: 9—almost 40) were 
selected for synthesis. Synthesis and biological evaluation of inhibitors 7–9 have been presented 
recently [39]. 
Figure 10. Structures of designed acetylcholinesterase inhibitors—newly synthesized  
(4–6) and currently described compounds (7–9).  
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All designed compounds were arranged along the gorge of acetylcholinesterase, interacting in a 
similar manner. They created interactions with main amino acids, Trp84, Phe330 and Trp279, and the 
hydrogen bond with a water molecule. 
Table 4. Assessment of the investigated compounds as potential AChE inhibitors. 
Compound ChemScore AChE IC50 AChE (nM) 
4 45.29 330 
5 41.83 170 
6 41.91 87.2 
7 40.54 920 
8 41.35 1070 
9 38.42 1230 
donepezil 49.48 31.2 
IC50 values were determined in Ellman’s assay [37,39]. The reference compound, donepezil, was placed in 
the table for comparison. 
In the case of butyrylcholinesterase, compounds 4–9 were arranged in a similar way, but their 
conformations were slightly bent, not linear, as for AChE. The fit of the new compounds was not as 
good as in the case of AChE, suggesting that these compounds might inhibit acetylcholinesterase 
stronger than butyrylcholinesterase. The structures interacted with two main amino acids Trp82 and 
Trp231. They formed a characteristic π–π and cation-π interactions. The linkers between the outermost 
elements of the molecule were involved in the hydrophobic interactions with the aromatic ring  
of Tyr332. 
Six compounds, which were designed according to the fragments, were synthesized and tested  
in Ellman’s assay [37]. They showed selective acetylcholinesterase inhibitory activity with  
micro- and submicromolar IC50 values, confirming the expectations based on the molecular  
modeling results. The most active was compound 6, with IC50 = 87 nM. This was  
2-(5-(2-fluorobenzylamino)pentyl)isoindoline-1,3-dione, a heterodimeric structure composed of  
o-fluorobenzylamine, phthalimide and a five-carbon chain. The inhibitor showed a binding mode with 
an extended conformation. The benzyl moiety created CH-π interactions with Trp84. The protonated 
amine group created cation-π interactions with Phe330. It was also engaged in an H-bond network: 
amine group-water molecule-Tyr121. The tether was located in the middle of the active gorge, near the 
aromatic amino acids, Phe290, Phe331 and Tyr334, where it creates hydrophobic interactions. The 
phthalimide moiety forms π–π stacking with Trp279 and CH-π interactions with Tyr70. Both carbonyl 
groups are engaged in H-bonds: one with Tyr121 and the other with water. The fluorine atom gave an 
additional H-bond with Ser200, which increased the activity in comparison with the unsubstituted 
compound 5 (87 nM vs. 170 nM). Also, the elongation of the linker (compound 4, IC50 = 330 nM) 
slightly decreased the activity, because in this case, the fit to the PAS and the anionic subsite in the 
CAS was worse. Compounds 7–9 with the diethylamine group were less active (0.92–1.23 μM) [39], 
because the aliphatic substituents (ethyl groups) could not provide as strong interactions as the 
aromatic phenyl ring in the benzylamine moiety. In the case of butyrylcholinesterase, due to the 
reduced peripheral binding site, interactions were weaker, and so, it led to inactivity against  
that enzyme. 
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2.5. Chemistry 
The synthesis of the desired compounds was accomplished as illustrated in Figure 11.  
2-Bromoalkylisoindole-1,3-diones (A–C) were prepared according to previously reported methods [39–41] 
in the reaction of potassium phthalimide and the appropriate dibromoalkane in acetonitrile with 
catalytic amount of tetra-n-butylammonium bromide (TBAB). They were used for preparation of final 
compounds 1–6 in the reaction with commercially available 4-amino-1-benzylpiperidine, benzylamine, 
2-florobenzylamine and with 1-(3-chlorobenzyl)piperidin-4-amine, which was prepared as described 
below. The reaction conditions were adjusted to the substrates used, compounds 1–3 were prepared 
either by heating under a reflux or in a microwave synthesizer, whereas compounds 4–6 were obtained 
at room temperature.  
Figure 11. Reagents and conditions: i. dibromoalkane, tetra-n-butylammonium bromide 
(TBAB), MeCN, reflux, 20 h; ii. (a) 4-amino-1-benzylpiperidine, triethylamine (TEA), 
MeCN, reflux, 3 h (compound (cmp.) 1,2); (b) 1-(3-chlorobenzyl)piperidin-4-amine, TEA, 
MeCN, microwave (MW), 100 °C, 45 min. (cmp. 3); (c) benzylamine, K2CO3, MeCN, 
room temperature (RT), 48 h (cmp. 4,5); (d) 2-fluorobenzylamine, K2CO3, MeCN, RT,  
48 h (cmp. 6). 
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1-(3-Chlorobenzyl)piperidin-4-amine [42] was prepared starting with 1-benzyl-4-aminopiperidine, 
whose amine group was tert-butyloxycarbonyl (BOC)-protected in the reaction with di-tert-butyl 
dicarbonate in tetrahydrofuran (THF). The obtained product was then debenzylated in methanol at 
atmospheric pressure of hydrogen and with a catalytical amount of 10% Pd/C and alkylated with  
3-chlorobenzyl bromide in THF. The final product was obtained by BOC-deprotection in 10% HCl 
solution in methanol.  
The final products were transformed into hydrochloride salts by adding to their solution isopropanol 
saturated with HCl.  
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2.6. Biological Assays  
The activity against acetylcholinesterases from electric eel and butyrylcholinesterase from horse 
serum was determined in spectrophotometric Ellman’s assay. Tacrine and donepezil were used as 
reference compounds. The dose-response curve enabled us to calculate IC50 values and 95% 
confidence intervals. Both values for the activity of all compounds against cholinesterases are 
summarized in Table 5. 
Table 5. Anticholinesterases activity of designed compounds. 
Compound AChE AChE BuChE BuChE 
 IC50 (μM) 95% CI (μM) IC50 (μM) 95% CI (μM) 
1 18.2 14.2–23.3 22.8 13.1–39.8 
2 53.7 40.6–71.1 24.5 15.9–37.7 
3 44.0 40.2–48.3 7.66 5.92–9.91 
4 0.330 0.313–0.348 n.a. n.a. 
5 0.170 0.153–0.188 n.a. n.a. 
6 0.0872 0.0777–0.0980 n.a. n.a. 
7 0.922 0.772–1.100 67.5 59.9–76.1 
8 1.07 0.88–1.30 n.a n.a. 
9 1.23 1.06–1.42 n.a n.a. 
Donepezil 0.0312 0.0274–0.0355 2.84 2.49–3.24 
Tacrine 0.0503 0.0465–0.0543 0.00536 0.00439–0.00655 
n.a.: not active; 95% CI: 95% confidence interval. 
3. Experimental Section 
3.1. Docking  
The structures were prepared in the following way. 
3.1.1. Ligands 
The 3D structures of all ligands were created by Corina on-line (Molecular Networks) [43] and 
saved as PDB files. Using Sybyl 8.0 (Tripos, St. Louis, MO, USA) [44], atom types were checked, 
protonation states were assigned, missing hydrogen atoms were added and Gasteiger charges were 
assigned. Finally, the compound structures were saved in mol2 format. 
3.1.2. Acetylcholinesterase 
During the protein preparation (PDB: 1EVE [34]), all histidine residues were protonated at Nε, the 
hydrogen atoms were added, ligand molecules were removed, the binding site was defined as all amino 
acid residues within 10 Å from donepezil and three water molecules (1159, 1249, 1254) were included. 
Dockings were performed with Gold 4.1 [36]. A standard set of genetic algorithm with a population 
size of 100, a number of operations of 100,000 and clustering with a tolerance of 1 Å was applied. 
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ChemScore was used for evaluation of the docking results. For each ligand, the final results involved 
10 poses, arranged on the ranking list, according to the scoring function values. 
3.1.3. Butyrylcholinesterase 
The enzyme structure (PDB: 1P0I [34]) was prepared for docking with Gold 4.1 [36]. Hydrogen 
atoms for the entire protein were added, protonating all histidine residues at Nε. Ligand molecules 
were removed, and the binding site was defined as the amino acid residues within 20 Å from the 
glycerol molecule, present in the active center of the enzyme. In the process of docking, water 
molecules that were present in the active center were taken into account, setting them as “toggle”, i.e., 
the program decided whether to include them or not. A standard set of genetic algorithms with a 
population size of 100, a number of operations of 100,000 and clustering with a tolerance of 1 Å was 
applied, and the ChemScore function was used for scoring. As a result, 10 ligand poses, sorted by the 
scoring function value, were obtained. 
3.2. Synthesis and Biological Assay  
3.2.1. General Information 
3.2.1.1. Chemistry 
Microwave reactions were performed in a Discover LabMate from CEM Corporation. Column 
chromatography was performed on Merck silica gel 60 (63–200 μm). Analytical thin layer 
chromatography was done using aluminum sheets precoated with silica gel 60 F254. Analytical  
RPLC-MS was performed on Waters Acquity TQD with a mass spectrometer (Waters TQD, Milford, 
MA, USA) with detection by UV (DAD) using an Acquity UPLC BEH C18 column (1.7 μm,  
2.1 × 100 mm). The CH3CN/H2O gradient with 0.1% HCOOH was used as the mobile phase at a flow 
rate of 0.3 mL/min. 1H NMR spectra were recorded on Varian Mercury 300 at 300 MHz. The chemical 
shifts for 1H NMR are referenced to TMS via residual solvent signals (1H, CDCl3 at 7.26 ppm, 
(CD3)2SO at 2.50 ppm). Elemental analyses were performed on a Vario EL III Elemental analyzer. All 
the compounds showed purity above 95%. The purity was determined by elemental analyses or on an 
analytical RPLC-MS on a Waters Acquity TQD using an Acquity UPLC BEH C18 column (1.7 μm, 
2.1 × 100 mm) at 214 nm and 254 nm. The CH3CN/H2O gradient with 0.1% HCOOH was used as the 
mobile phase at a flow rate of 0.3 mL/min. 
The following compounds: 2-(3-bromopropyl)isoindoline-1,3-dione (A) [40],  
2-(5-bromopentyl)isoindoline-1,3-dione (B) [39], 2-(6-bromohexyl)isoindoline-1,3-dione (C) [41],  
1-(3-chlorobenzyl)piperidin-4-amine [42], 2-(8-diethylaminooctyl)-isoindoline-1,3-dione (7) [39],  
2-(7-diethylaminoheptyl)-isoindoline-1,3-dione (8) [39] and 2-(6-diethylaminohexyl)-isoindoline-1,3-
dione (9) [39], were previously reported. 
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3.2.1.2. Materials 
All the reagents were purchased from commercial suppliers and were used without further 
purification. Tetrahydrofuran (THF) was distilled under nitrogen immediately before use; a mixture of 
sodium/benzophenone ketyl was used as a drying agent. 
3.2.1.3. Biological Activity 
The activity against cholinesterases was determined in spectrophotometric Ellman’s assay [37]. 
3.2.2. Experimental Details and Spectroscopic Data 
2-(3-Bromopropyl)isoindoline-1,3-dione (A) [40]  
1H NMR (300 MHz, CDCl3) δ ppm: 7.81–7.85 (m, 2H), 7.70–7.75 (m, 2H), 3.83 (t, J = 6.83 Hz, 
2H), 3.41 (t, J = 6.75 Hz, 2H), 2.26 (q, J = 6.80 Hz, 2H).  
2-(5-Bromopentyl)isoindoline-1,3-dione (B) [39] 
1HNMR (CDCl3) δ ppm: 7.80–7.86 (m, 2H, Pht–H), 7.63–7.74 (m, 2H, Pht-H), 3.69 (t, J = 7.19 Hz, 
2H, PhtCH2), 3.39 (t, J = 6.75 Hz, 2H, BrCH2), 1.85–1.95 (m, 2H, BrCH2CH2), 1.56–1.68 (m, 2H, 
PhtCH2CH2), 1.44–1.54 (m, 2H, Br(CH2)2CH2).
 
2-(6-Bromohexyl)isoindoline-1,3-dione (C) [41] 
A mixture of potassium phthalimide (27.0 mmol, 5.00 g), 1,6-dibromohexane (67.5 mmol,  
10.42 mL) and a catalytic amount of TBAB (1.0 mmol, 0.32 g) in acetonitrile (70.0 mL) was refluxed 
for 20 h. After the mixture was cooled down to room temperature, the solid salts were filtered off and 
the resulting filtrate was evaporated. The crude product was purified by column chromatography using  
n-hexane to wash out the access of 1,6-dibromohexane and n-hexane/EtOAc (7/3) for further 
purification. 6.76 g (81%) of a pure product was obtained. 1H NMR (300 MHz, CDCl3) δ ppm:  
7.80–7.87 (m, 2H), 7.68–7.73 (m, 2H), 3.68 (t, J = 7.19 Hz, 2H), 3.39 (t, J = 6.79 Hz, 2H), 1.80–1.90 
(m, 2H), 1.64–1.74 (m, 2H), 1.3–1.53 (m, 4H). 
1-(3-Chlorobenzyl)piperidin-4-amine [42] 
To a solution of 1-benzyl-4-aminopiperidine (70.0 mmol, 14.3 mL) and TEA (210.0 mmol,  
29.3 mL) in 80.0 mL of THF cooled on an ice-bath, di-tert-butyl dicarbonate (77.0 mmol, 16.80 g) 
solution in 80.0 mL of THF was slowly added. The reaction mixture was warmed up to room 
temperature and left overnight. After the reaction was finished, the solvent was removed, and the 
obtained precipitate was dissolved in 250.0 mL of ethyl acetate and extracted with water  
(3 × 100.0 mL). The combined organic layers were dried over anhydrous Na2SO4 filtered and 
concentrated under vacuum to give 1-benzyl-4-(tert-butoxycarbonylamino)piperidine as a white solid 
19.8 g (97%), MS: m/z 291 (M+H+). 
To a solution of 1-benzyl-4-(tert-butoxycarbonylamino)piperidine (17.2 mmol, 5.00 g) in methanol 
(200.0 mL), 10% Pd/C (0.50 g) was added, and the mixture was hydrogenated at atmospheric pressure 
for 8 h. After this time, another portion of 10% Pd/C (0.50 g) was added, and the mixture was again 
left at atmospheric pressure of hydrogen for 8 hours; after that, the procedure was repeated again. After 
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24 h, the mixture was filtered through a Celite pad, concentrated under vacuum and  
purified by column chromatography in DCM/MeOH/TEA (85/10/5) to give 2.87 g (83%) of  
4-(tert-butoxycarbonylamino)piperidine as a white solid. 1H NMR (300 MHz, CDCl3)  
δ ppm: 4.43–4.58 (m, 1H), 3.43–3.63 (m, 1H), 3.03–3.10 (m, 2H), 2.62–2.71 (m, 2H), 2.40 (s, 1H), 
1.91–1.96 (m, 2H), 1.44 (s, 9H), 1.23–1.37 (m, 2H); MS: m/z 201 (M+H+). 
To a solution of 4-(tert-butoxycarbonylamino)piperidine (10.0 mmol, 2.00 g) in 25.0 mL of 
anhydrous THF, 3-chlorobenzyl bromide (10.0 mmol, 1.32 mL) was added, and the mixture was 
refluxed for 24 h. After the reaction was finished, the solvent was evaporated and the crude product 
was purified by column chromatography on silica gel (DCM/MeOH, 95/5) to give 1.92 g (59%) of 
tert-butyl 1-(3-chlorobenzyl)piperidin-4-ylcarbamate as a white solid. 1H NMR (300 MHz, CDCl3)  
δ ppm: 7.32 (s, 1H), 7.15–7.25 (m, 3H), 4.38–4.50 (m, 1H), 3.45 (s, 3H), 2.76–2.80 (m, 2H), 2.05–2.14 
(m, 2H), 1.85–1.97 (m, 2H), 1.37–1.51 (m, 11H); MS: m/z 325 (M+H+). 
Tert-butyl-1-(3-chlorobenzyl)piperidin-4-ylcarbamate (11.3 mmol, 3.65 g) was dissolved in  
100.0 mL 10% HCl in MeOH and was left stirring at room temperature for 24 h. After this time, the 
solvent was evaporated and the obtained oil was neutralized with 6 N NaOH and extracted with DCM 
and EtOAc (5 × 20 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and 
evaporated under vacuum to give the desired product as a brownish oil (0.92 g, 35%). 1H NMR  
(300 MHz, DMSO-d6) δ ppm: 11.30 (br. s., 1H), 8.50 (br. s., 2H), 7.78 (s, 1H), 7.40–7.64 (m, 3H), ), 
4.26 (br. s., 2H), 3.15–3.35 (m, 3H), 2.97–3.08 (m, 2H), 1.89–2.23 (m, 4H); MS: m/z 225 (M+H+). 
2-(3-(1-Benzylpiperidin-4-ylamino)propyl)isoindoline-1,3-dione (1) 
A mixture of 2-(3-bromopropyl)isoindole-1,3-dione (5.0 mmol, 1.34 g),  
4-amino-1-benzylpiperidine (5.0 mmol, 0.95 g) and TEA (6.0 mmol, 0.60 g) in 15.0 mL of acetonitrile 
was refluxed for 3 h. After cooling to room temperature, the expected product precipitated as a 
hydrobromide salt. It was collected by filtration, washed with MeCN and dried in vacuo. The obtained 
product was dissolved in 25.0 mL of water, and then, it was adjusted to basic pH with 25% NH4OH 
solution. Then, the product was extracted with dichloromethane (3 × 25.0 mL). The combined extracts 
were dried over anhydrous Na2SO4 to give 0.94 g (50%) of colorless oil. 
1H NMR (300 MHz, CDCl3) 
δ ppm: 7.78–7.84 (m, 2H, Pht–H), 7.67–7.75 (m, 2H, Pht–H), 7.26–7.45 (m, 5H, ArH), 3.84 (t,  
J = 6.31 Hz, 2H, PhtCH2), 3.68 (s, 2H, benzylCH2), 2.87–3.15 (m, 5H: 3H, Ppd, 2H, NHCH2),  
2.19–2.38 (m, 6H: 4H, Ppd, 2H PhtCH2CH2), 1.88–1.99 (m, 2H, Ppd), NH signal not detected. MS: 
m/z 378 (M+H+). Analysis calculated (Anal. calcd.) for C23H29N3O2Cl2: (%) C, 61.33; H, 6.49; N, 9.33. 
Found: C, 61.06; H, 6.35; N, 8.85. 
2-(6-(1-Benzylpiperidin-4-ylamino)hexyl)isoindoline-1,3-dione (2) 
A mixture of 2-(6-bromohexyl)isoindole-1,3-dione (5.0 mmol, 1.48 g), 4-amino-1-benzylpiperidine 
(5.0 mmol, 0.95 g) and TEA (6.0 mmol, 0.60 g) in 15.0 mL of acetonitrile was refluxed for 3 h. After 
cooling, the expected product precipitated as a hydrobromide salt. It was collected by filtration, 
washed with MeCN and dried in vacuo. The obtained product was dissolved in 25.0 mL of water and 
then was adjusted to basic pH with 25% NH4OH solution. Then, the product was extracted with 
dichloromethane (3 × 25.0 mL). The combined extracts were dried over anhydrous Na2SO4 to give 
1.40 g (67%) of colorless oil. 1H NMR (300 MHz, CDCl3) δ ppm: 7.78–7.84 (m, 2H, Pht–H),  
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7.66–7.71 (m, 2H, Pht–H), 7.22–7.30 (m, 5H, ArH), 3.63 (t, J = 7.04 Hz, 2H, PhtCH2), 3.52 (s, 2H, 
benzylCH2), 2.82–3.04 (m, 5H: 2H, NHCH2, 3H, Ppd), 1.79–2.19 (m, 8H: 6H, Ppd, 2H, NHCH2CH2), 
1.59–1.73 (m, 2H, PhtCH2CH2), 1.28–1.46 (m, 4H, Pht(CH2)2(CH2)2), NH signal not detected.  
MS: m/z 420 (M+H+). Anal. calcd. for C26H35N3O2Cl2 (%) C, 63.41; H, 7.16; N, 8.53. Found: C, 
63.23; H, 7.18; N, 8.50. 
2-(6-(1-(3-Chlorobenzyl)piperidin-4-ylamino)hexyl)isoindoline-1,3-dione (3) 
A 2–5 mL microwave-transparent process vial was charged with 2-(6-bromohexyl)isoindoline-1,3-
dione (0.35 mmol, 108.6 mg), 1-(3-chlorobenzyl)piperidin-4-amine (0.35 mmol, 78.7 mg), TEA  
(0.42 mmol, 58.6 μL) and acetonitrile (2.0 mL). The mixture was exposed to microwave heating for  
45 min at 100 °C. After the mixture was cooled, the solvent was evaporated and the crude product was 
purified by column chromatography in DCM/MeOH (9/1) to give 0.11 g (70%) of a white solid.  
1H NMR (300 MHz, CDCl3) δ ppm: 7.79–7.85 (m, 2H, Pht–H), 7.68–7.74 (m, 2H, Pht–H), 7.32 (s, 
1H, ArH), 7.20–7.25 (m, 3H, ArH), 3.65 (t, J = 7.05 Hz, 2H, PhtCH2), 3.50 (s, 2H, benzylCH2),  
3.03–3.15 (m, 1H, Ppd), 2.89–3.01 (m, 4H: 2H, NHCH2, 2H, Ppd), 2.18–2.22 (m, 2H, Ppd),  
1.88–2.13 (m, 6H: 4H Ppd, 2H NHCH2CH2), 1.63–1.73 (m, 2H, PhtCH2CH2), 1.30–1.50 (m, 4H, 
Pht(CH2)2(CH2)2); MS: m/z 454 (M+H
+). 
2-(6-(Benzylamino)hexyl)isoindoline-1,3-dione (4) 
A mixture of 2-(6-bromohexyl)isoindole-1,3-dione (0.50 mmol, 0.16 g), benzylamine (1.50 mmol, 
0.16 g) and K2CO3 (1.50 mmol, 0.21 g) was stirred in 20.0 mL acetonitrile for 48 h. After the reaction 
was finished, the solvent was evaporated and the obtained residue was dissolved in 20.0 mL water and 
extracted with chloroform (4 × 10.0 mL). The organic layer was dried over Na2SO4 and evaporated. 
The crude product was purified by column chromatography in CHCl3/MeOH (98/2, 95/5) to give  
78.0 mg (46%) of a yellow oil. 1 H NMR (300 MHz, CDCl3) δ ppm: 7.84–7.81 (m, 2H, Pht), 7.73–7.68 
(m, 2H, Pht), 7.45–7.26 (m, 5H, Ph), 3.89 (s, 2H, CH2Ph), 3.67 (t, J = 7.2 Hz, 2H, PhtCH2), 2.68 (t,  
J = 7.5 Hz, 2H, (CH2)5CH2NH), 1.71–1.60 (m, 2H, PhtCH2CH2), 1.37–1.25 (m, 6H, Pht(CH2)2(CH2)3), 
NH signal not detected; MS: m/z 337 (M+H+). 
2-(5-(Benzylamino)pentyl)isoindoline-1,3-dione (5)  
A mixture of 2-(5-bromopentyl)isoindole-1,3-dione (0.50 mmol, 0.15 g), benzylamine (1.50 mmol, 
0.16 g) and K2CO3 ( 1.50 mmol, 0.21 g) was stirred in 20.0 mL acetonitrile for 48 h at room 
temperature. After the reaction was finished, the solvent was evaporated and the obtained residue was 
dissolved in 20.0 mL water and extracted with chloroform (4 × 10.0 mL). The organic layer was dried 
over Na2SO4 and evaporated. The crude product was purified by column chromatography in 
CHCl3/MeOH (98/2, 95/5) to give 80.0 mg (50%) of a yellow oil. The final product was obtained in 
the form of hydrochloride salt. 1 H NMR (300 MHz, (CD3)2SO) δ ppm: 9.00 (s, 2H, NH2
+), 7.87–7.81 
(m, 4H, Pht), 7.51–7.49 (m, 2H, Ph), 7.41–7.39 (m, 3H, Ph), 4.10–4.06 (t, J = 5.8 Hz, 2H, 
NH2
+CH2Ph), 3.55 (t, J = 7.0 Hz, 2H, PhtCH2), 2.89–2.80 (m, 2H, (CH2)4CH2NH2
+), 1.67–1.62  
(m, 2H, CH2CH2NH2
+), 1.61–1.55 (m, 2H, PhtCH2CH2), 1.31–1.27 (m, 2H, (CH2)2CH2(CH2)2);  
MS: m/z 323 (M+H+). 
Int. J. Mol. Sci. 2013, 14 5628 
 
 
2-(5-(2-Flourobenzylamino)pentyl)isoindoline-1,3-dione (6) 
A mixture of 2-(5-bromopentyl)isoindole-1,3-dione (0.50 mmol, 0.15 g), 2-florobenzylamine  
(1.50 mmol, 0.19 g) and K2CO3 (1.50 mmol, 0.21 g) was stirred in 20.0 mL acetonitrile for 48 h. After 
the reaction was finished, the solvent was evaporated and the obtained residue was dissolved in  
20.0 mL water and extracted with chloroform (4 × 10.0 mL). The organic layer was dried over Na2SO4 
and evaporated. The crude product was purified by column chromatography in CHCl3/MeOH (98/2, 
95/5) to give 80.0 mg (47%) of a yellow oil. 1 H NMR (300 MHz, CDCl3) δ ppm: 7.88–7.79 (m, 2H, 
Pht), 7.73–7.67 (m, 2H, Pht), 7.36–7.28 (m, 1H, Ph), 7.23–7.18 (m, 1H, Ph), 7.11–6.98 (m, 2H, Ph),  
3.79 (s, 2H, CH2phenyl), 3.67 (t, J = 7.2 Hz, 2H, PhtCH2), 2.61 (t, J = 7.2 Hz, 2H, (CH2)4CH2NH), 
1.73–1.66 (m, 2H, PhtCH2CH2), 1.61–1.51 (m, 2H,CH2CH2NH), 1.43–1.32 (m, 2H, (CH2)2CH2(CH2)2), 
NH signal not detected; MS: m/z 341 (M+H+). 
3.2.3. Ellman’s Assay—AChE/BuChE Inhibition Activity 
Reagents and chemicals—acetylthiocholine iodide, butyrylthiocholine iodide, AChE from 
Electrophorus electricus (425.96 U/mg solid), BuChE from horse serum (2.5 units/1 mL) and 
DNTB—were purchased from Sigma–Aldrich. All assays were performed using the Perkin Elmer 
Lambda 12 device with detection at 412 nm. The reaction took place in 100 mM phosphate buffer,  
pH 8.0, containing 0.25 units of AChE or BuChE, 0.3 mmol 5,5'-dithio-bis-(2-nitrobenzoic) acid 
(DTNB) and 0.45 mmol acetylthiocholine or butyrylthiocholine as substrates. The tested compounds 
were incubated with the enzyme for 5 min at 25 °C prior to starting the reaction by adding the 
substrate. Enzymatic activity was determined by measuring absorbance over a period of 5 min. Two 
kinds of assays were conducted: the peak activity of the enzyme was determined by using a blank 
sample, followed by reference measurements (for tacrine and donepezil, see table below) and 
measurements for the synthesized compounds. Data from concentration-inhibition experiments were 
integrated through nonlinear regression analysis using the GraphPad Prism program (GraphPad Prism 
Software Inc. 2005, La Jolla, CA, USA), producing estimates of IC50. 
4. Conclusions  
Molecular modeling studies allowed us to propose new structures as potential cholinesterase 
inhibitors, derived from a previously developed library or from structural fragments. 
According to the modeling studies, compound 1 and 2 bind through the main and peripheral AChE 
active site due to π–π stacking interactions with Trp84 and Trp279 residues. We assume that these 
interactions are responsible for the inhibitory activity of these compounds against acetylcholinesterase 
and against β-amyloid aggregation. On the basis of these structures, new derivatives with potentially 
enhanced activity were designed. The design included changes of the heterocyclic system, the length 
of the linker and the introduction of substituents into the benzyl moiety. As heterocyclic systems, 
phthalimide, indole, tetrahydroisoquinoline, tetrahydroquinoline and isoindoline were sequentially 
tested computationally. The most preferred fragment for the short linker (three carbon atoms) was 
phthalimide. The analysis of the influence of substituents in the benzyl moiety on potential activity 
involved fluorine, chlorine, hydroxy, methoxy and trifluoromethyl groups and dimethyl or ethyl 
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carbamate. For all substituents, it was examined which position in the phenyl ring was most preferred. 
It was found that p-hydroxy, m-chloro and o-fluoro derivatives were the highest rated. For the six 
carbon linker, different heterocyclic rings obtained similar score, but in the case of an eight-carbon 
linker, three moieties were distinguished: isoindoline, tetrahydroquinoline and indole. In every case,  
p-hydroxy, m-chloro and o-fluoro derivatives were better than unsubstituted compounds. Derivative 3 
(m-chloro analogue of compound 2) was obtained, and it was an inhibitor of both cholinesterases with 
improved activity (AChE: 44.0 μM, BuChE: 7.66 μM). 
These results, the fragment-based design technique and literature data were used for further design 
of potential inhibitors of cholinesterases. In this way, novel compounds with different amine moieties 
(benzylamine, o-fluorobenzylamine or diethylamine) were designed and preliminary studies on 
synthesis and biological evaluation were made. The obtained and currently described [39] results 
confirmed that the investigated compounds 4–9 were selective inhibitors of AChE with IC50 values in 
the range 0.087–1.23 μM. They were more potent inhibitors than parent compounds from our library, and 
some of them displayed beta-amyloid anti-aggregating activity, which leads to the assumption that they 
might be dual binding site inhibitors. It is worthwhile to note that the IC50 value against acetylcholinesterase 
for the most active compound, 6 (87 nM), was in the same range as for donepezil (31 nM). 
Summing up, the described structure-based search methodology led to the discovery of 
cholinesterase inhibitors with activities improved from the micromolar to the mid-nanomolar range. 
This approach could represent a useful tool for the discovery of novel cholinesterases inhibitors 
potentially endowed with additional properties. 
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